Related Experiment Video

Updated: Jun 3, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Thiazolidenediones induce tumour-cell apoptosis through the Akt-GSK3β pathway

H Zhu1, B Han, X Pan

  • 1Department of Pathophysiology, Medical College of Qingdao University, Qingdao University, Qingdao, China.

Journal of Clinical Pharmacy and Therapeutics
|March 18, 2011
PubMed
Abstract

Insights

Thiazolidinediones (TZDs) trigger prostate cancer cell death by inhibiting Akt and inactivating GSK3β. This modulation of the Akt-GSK3β pathway offers a novel therapeutic strategy for prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Prostate cancer remains a significant health concern for men globally.
  • Thiazolidinediones (TZDs) are known to induce apoptosis in prostate cancer cells, independent of PPARγ activation.
  • The precise molecular mechanisms underlying TZD-induced apoptosis are not fully understood.

Purpose of the Study:

  • To investigate the effects of TZDs on apoptosis in prostate cancer cells.
  • To elucidate the role of the Akt and GSK3β signaling pathways in TZD-mediated apoptosis.
  • To explore potential therapeutic strategies targeting the Akt-GSK3β cascade.

Main Methods:

  • Cultured LNCaP prostate cancer cells.
  • Assessed cell viability using MTT assays.
  • Analyzed total and phosphorylated Akt and GSK3β protein levels via Western blotting.

Main Results:

  • TZDs inhibit Akt phosphorylation, contributing to apoptosis in prostate cancer cells.
  • TZDs induce inactivation of glycogen synthase kinase 3β (GSK3β).
  • Lithium chloride, a GSK3β inhibitor, enhances TZD-induced cytotoxicity.

Conclusions:

  • The Akt-GSK3β pathway is implicated in TZD-induced apoptosis of prostate cancer cells.
  • Targeting the Akt-GSK3β cascade presents a potential therapeutic avenue for prostate cancer treatment.
  • This study reveals a novel mechanism for TZD action in prostate cancer apoptosis.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...